SlideShare a Scribd company logo
1 of 33
EMERGENCY MEDICINE
• SHOCK
• Types of shock
Dr. Chongo Shapi (BSc.HB, MBChB).
Medical Doctor
21 March 2024 1
Dr. Chongo Shapi (BSc. HB, MBChB)
INTRODUCTION
• Circulatory failure resulting in inadequate
organ perfusion. Often defined by Reduced
BP— systolic <90mmHg—or mean arterial
pressure (MAP) <65mmHg—with evidence of
tissue hypoperfusion, eg mottled skin, urine
output (UO) of <0.5mL/kg/h, serum lactate
>2mmol/L.
21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 2
CONT’
• Signs: Reduced GCS/agitation, pallor, cool
peripheries, tachycardia, slow capillary refill,
tachypnoea, oliguria.
• MAP = cardiac output (CO) ≈ systemic vascular
resistance (SVR). CO = stroke volume ≈ heart
rate.
• Therefore, shock can result from inadequate
CO or a loss of SVR, or both.
21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 3
CONT’
Inadequate cardiac output
• Hypovolaemia:
• Bleeding: trauma, ruptured aortic aneurysm, GI bleed.
• Fluid loss: vomiting, burns, ‘third-space’ losses, eg
pancreatitis, heat exhaustion.
• Pump failure:
• Cardiogenic shock, eg ACS, arrhythmias, aortic
dissection, acute valve failure.
• Secondary causes, eg PE, tension pneumothorax,
cardiac tamponade.
21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 4
CONT’
• Peripheral circulatory failure (loss of SVR)
• Sepsis: Infection with any organism can cause
acute vasodilation from inflammatory cytokines.
Gram –ve’s can produce endotoxin, causing
sudden and severe shock but without signs of
infection (fever, Raised WCC). Classically patients
with sepsis are warm & vasodilated, but may be
cold & shut down.
• Other diseases, eg pancreatitis, can give a similar
picture associated with the inflammatory
cascade.
21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 5
CONT’
• Anaphylaxis:
• Neurogenic: Eg spinal cord injury, epidural or
spinal anaesthesia.
• Endocrine failure: Addison’s disease, p836 or
hypothyroidism;
• Other: Drugs, eg anaesthetics,
antihypertensives, cyanide poisoning.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 6
APPROACH
• With shock we are dealing primarily with ‘C ’
so get large-bore IV access ≈2 and check ECG
for rate, rhythm (very fast or very slow will
compromise cardiac output), and signs of
ischaemia.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 7
CONT’
• General review: Cold and clammy suggests
cardiogenic shock or fluid loss. Look for signs
of anaemia or dehydration, eg skin turgor,
postural hypotension? Warm and well
perfused, with bounding pulse points to septic
shock.
• Any features suggestive of anaphylaxis—
history, urticaria, angioedema, wheeze?
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 8
CONT’
• CVS: Usually tachycardic (unless on B-blocker, or in
spinal shock— and hypotensive.
• But in the young and fit, or pregnant women, the
systolic BP may remain normal, although the pulse
pressure will narrow, with up to 30% blood volume
depletion.
• Difference between arms (>20mmHg)—aortic
dissection?
• JVP or central venous pressure: If raised, cardiogenic
shock likely.
• Check abdomen: Any signs of trauma, or aneurysm?
Any evidence of GI bleed?
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 9
MANAGEMENT
• Depends on the type of shock:
a) Septic shock:
b) Anaphylaxis:
c) Cardiogenic shock:
d) Hypovolaemic shock
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 10
HYPOVOLEMIC
SHOCK
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 11
HYPOVOLEMIC SHOCK
• Identify and treat underlying cause. Raise the
legs.
• Give fluid bolus 10–15mL/kg crystalloid via
large peripheral line, if shock improves,
• repeat, titrate to HR (aim <100), BP (aim SBP
>90) and UO (aim >0.5mL/kg/h).
• If no improvement after 2 boluses, consider
referral to ICU
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 12
HAEMORRHAGIC
SHOCK
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 13
HAEMORRHAGIC SHOCK
• Stop bleeding if possible. Identification of grade is
significant.
• If still shocked despite 2L crystalloid or present
with class III/IV shock then crossmatch blood
(request O Rh–ve in an emergency).
• Give FFP with red cells (1 : 1 ratio); aim for
platelets >100 and fibrinogen >1 (guided by
results, but eg 1 pool of platelets and 2 pools of
cryoprecipitate per 6–8 units of red cells).
• Consider tranexamic acid 2g IV. Discuss with
haematology early.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 14
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 15
SHOCK
SEPSIS
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 16
SEPSIS
• Sepsis Life-threatening organ dysfunction caused
by a dysregulated host response to infection.
• Sepsis is a major killer. There are >150 000 cases
of sepsis in the UK each year resulting in >44 000
deaths, and much morbidity.
• Septic shock Sepsis in combination with:
a) EITHER lactate >2mmol/L despite adequate
fluid resuscitation
b) OR the patient is requiring vasopressors to
maintain MAP ≥65mmHg.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 17
CONT’
• Many sepsis-related deaths could be prevented with earlier
treatment. Often, the key failure in sepsis management is not
recognizing sepsis in time.
• Early warning scores help identify inpatients who are becoming
septic.
• Have a low threshold for assessing for sepsis if:
a) The patient has communication difficulties: limited English;
limited verbal communication or cognitive impairment
b) The patient is immunosuppressed, on chemotherapy, or an IV
drug user
c) The patient recently had surgery or is pregnant/recently gave birth
d) The patient has indwelling lines/other foreign material.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 18
ASSESSING RISK IN SEPSIS
MODERATE TO HIGH RISK
CRITERIA
• Reports of altered mental
state or acute deterioration
in functional status
• Respiratory rate (RR) 21–24
• Systolic blood pressure
(SBP) 91–100mmHg
• Heart rate 91–130bpm or
new arrhythmia.
• Urine output: nil for 12–
18h; 0.5–1.0mL/kg/h if
catheterized
HIGH RISK CRITERIA
• Objective evidence of
altered mental state
• RR>24; new requirement
for FiO2 >40% to keep sats
>92% (>88% in COPD)
• SBP <90 or >40mmHg less
than baseline
• Heart rate >130bpm
• Urine output: nil for 18h;
<0.5mL/kg/h if catheterized
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 19
CONT’
• Local signs of infection,
incl. redness, swelling, or
discharge around wound
• Rigors, or temperature
<36°C
• Impaired immunity
(illness or drugs)
• Recent
surgery/trauma/invasive
procedure
• Mottled, ashen, or
cyanotic skin. Non-
blanching rash
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 20
CONT’
• High risk: At least one high-risk criterion OR at
least two moderate- to high-risk criteria with
AKI or LACTATE >2.
• Moderate to high risk: At least one moderate-
to high-risk criterion.
• Low risk: No moderate- or high-risk criteria.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 21
ACUTE MANAGEMENT IN SEPSIS
• Early recognition and treatment is key.
• Antibiotics: These should be broad spectrum and start
within 1h. Consider covering for non-bacterial
microbes, eg give aciclovir if HSV encephalitis is
suspected.
• Fluids: Give within 1h if high risk with SBP <90, AKI, or
lactate >2 (consider if <2).
❑Give 500mL boluses of crystalloids with 130–
154mmol/L sodium (eg 0.9% saline) over 15mins.
Caution in heart failure.
❑ If no improvement after two boluses, speak with a
senior. (Possible use of inotropes)
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 22
CONT’
• Oxygen: Give oxygen as required for target saturations.
These will be 94–98% (or 88–92% if the patient is at
risk of CO2 retention, eg in severe COPD).
• Critical care review: Speak with critical care early if
intensive care support (eg inotropes, ventilation,
haemofiltration, intensive monitoring) may be
required.
• Surgical involvement: Eg emergency wound
debridement.
• Manage acute complications: Shock, AKI, DIC, ARDS,
arrhythmias etc (may spontaneously resolve when
sepsis improves).
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 23
SHOCK
ANAPHYLACTIC SHOCK
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 24
ANAPHYLACTIC SHOCK
• Type I IgE-mediated hypersensitivity reaction.
Release of histamine and other agents causes:
capillary leak; wheeze; cyanosis; oedema
(larynx, lids, tongue, lips); urticaria.
• More common in atopic individuals. An
anaphylactoid reaction results from direct
release of mediators from inflammatory cells,
without involving antibodies, usually in
response to a drug, eg acetylcysteine.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 25
CONT’
• Examples of precipitants:
a) Drugs, eg penicillin, and contrast media in
radiology.
b) Latex.
c) Stings, eggs, fish, peanuts, strawberries,
semen (rare).
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 26
CONT’
• Signs and symptoms
a) Itching, sweating, diarrhoea and vomiting,
erythema, urticaria, oedema.
b) Wheeze, laryngeal obstruction, cyanosis.
Tachycardia, hypotension.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 27
MANAGEMENT
• Secure the airway—give 100% O2 but Intubate if
respiratory obstruction imminent.
• Remove the cause; raising the feet may help
restore the circulation.
• Give adrenaline IM 0.5mg (ie 0.5mL of 1:1000).
Repeat every 5min, if needed as guided by BP,
pulse, and respiratory function, until better
• Give Chlorphenamine 10mg IV and
hydrocortisone 200mg IV
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 28
CONT’
• IVI (0.9% saline, eg 500mL over ¼h; up to 2L
may be needed) Titrate against blood
pressure.
• If wheeze, treat for asthma. May require
ventilatory support.
• If still hypotensive, admission to ICU and an
IVI of adrenaline may be needed ±
aminophylline and nebulized salbutamol
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 29
CONT’
• When stable, admit to ward. Monitor ECG
• Measure serum tryptase 1–6h after suspected
anaphylaxis
• Continue chlorphenamine 4mg/6h PO if itching
• Suggest a ‘MedicAlert’ bracelet naming the
culprit allergen
• Teach about self-injected adrenaline (eg 0.3mg,
Epipen®) to prevent a fatal attack
• Skin-prick tests showing specific IgE help identify
allergens to avoid
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 30
CONT’
• Adrenaline (=epinephrine) is given IM and
NOT IV unless the patient is severely ill, or has
no pulse. The IV dose is different:
100mcg/min—titrating with the response.
• This is 0.5mL of 1 : 10 000 solution IV per
minute. Stop as soon as a response has been
obtained.
• If on a B-blocker, consider salbutamol IV in
place of adrenaline.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 31
THE END!
• Reference as per Oxford Clinical Medicine.
22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 32
Thanks
21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 33

More Related Content

Similar to Shock (General Overview)... By Shapi.pdf

classification,recognition and management of shock
classification,recognition and management of shockclassification,recognition and management of shock
classification,recognition and management of shockDr. Shahnawaz Alam
 
Copy (2) of sepsis present เซกา revised
Copy (2) of sepsis present เซกา revisedCopy (2) of sepsis present เซกา revised
Copy (2) of sepsis present เซกา revisedKit GenSx
 
Management of shock
Management of shockManagement of shock
Management of shockswamy15
 
Acute upper gastrointestinal bleeding.pptx
Acute upper gastrointestinal bleeding.pptxAcute upper gastrointestinal bleeding.pptx
Acute upper gastrointestinal bleeding.pptxKTD Priyadarshani
 
Dr hamada alsedawy sepsis and aki
Dr hamada alsedawy   sepsis and akiDr hamada alsedawy   sepsis and aki
Dr hamada alsedawy sepsis and akiFarragBahbah
 
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdfCognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdfaddi33
 
Case Presentations 1
Case Presentations 1Case Presentations 1
Case Presentations 1Gamal Agmy
 
SHOCK AND ITS COMPLICATIONS.ppt
SHOCK AND ITS COMPLICATIONS.pptSHOCK AND ITS COMPLICATIONS.ppt
SHOCK AND ITS COMPLICATIONS.pptTbndkSamuelTesa
 
Shock its pathopysiology and management
Shock its pathopysiology and managementShock its pathopysiology and management
Shock its pathopysiology and managementSHAKIL JAWED
 
GI BLEED FOR NURSES.ppt
GI BLEED FOR NURSES.pptGI BLEED FOR NURSES.ppt
GI BLEED FOR NURSES.pptMazinAljabiri2
 
Upper gastrointestinal tract bleeding(ugib)
Upper gastrointestinal tract bleeding(ugib)Upper gastrointestinal tract bleeding(ugib)
Upper gastrointestinal tract bleeding(ugib)Joseph Ofoegbu
 

Similar to Shock (General Overview)... By Shapi.pdf (20)

Shock.pptx
Shock.pptxShock.pptx
Shock.pptx
 
classification,recognition and management of shock
classification,recognition and management of shockclassification,recognition and management of shock
classification,recognition and management of shock
 
SHOCK
SHOCKSHOCK
SHOCK
 
Copy (2) of sepsis present เซกา revised
Copy (2) of sepsis present เซกา revisedCopy (2) of sepsis present เซกา revised
Copy (2) of sepsis present เซกา revised
 
Management of Shock
Management of ShockManagement of Shock
Management of Shock
 
Upper GI Bleeding
Upper GI Bleeding Upper GI Bleeding
Upper GI Bleeding
 
Upper Git Bleeding
Upper Git BleedingUpper Git Bleeding
Upper Git Bleeding
 
Management of shock
Management of shockManagement of shock
Management of shock
 
Acute upper gastrointestinal bleeding.pptx
Acute upper gastrointestinal bleeding.pptxAcute upper gastrointestinal bleeding.pptx
Acute upper gastrointestinal bleeding.pptx
 
Dr hamada alsedawy sepsis and aki
Dr hamada alsedawy   sepsis and akiDr hamada alsedawy   sepsis and aki
Dr hamada alsedawy sepsis and aki
 
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdfCognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
Cognitive-Aids-for-Neuroanesthetic-Emergencies.pdf
 
Hm
HmHm
Hm
 
Shock.pptx
Shock.pptxShock.pptx
Shock.pptx
 
Case Presentations 1
Case Presentations 1Case Presentations 1
Case Presentations 1
 
SHOCK AND ITS COMPLICATIONS.ppt
SHOCK AND ITS COMPLICATIONS.pptSHOCK AND ITS COMPLICATIONS.ppt
SHOCK AND ITS COMPLICATIONS.ppt
 
Shock its pathopysiology and management
Shock its pathopysiology and managementShock its pathopysiology and management
Shock its pathopysiology and management
 
GI BLEED FOR NURSES.ppt
GI BLEED FOR NURSES.pptGI BLEED FOR NURSES.ppt
GI BLEED FOR NURSES.ppt
 
septic shock presentation. a majot threat to Surgeon
septic shock presentation. a majot threat to Surgeonseptic shock presentation. a majot threat to Surgeon
septic shock presentation. a majot threat to Surgeon
 
Shock
ShockShock
Shock
 
Upper gastrointestinal tract bleeding(ugib)
Upper gastrointestinal tract bleeding(ugib)Upper gastrointestinal tract bleeding(ugib)
Upper gastrointestinal tract bleeding(ugib)
 

More from Shapi. MD

Hearing loss (Ear Nose and Throat)... By Shapi.pdf
Hearing loss (Ear Nose and Throat)... By Shapi.pdfHearing loss (Ear Nose and Throat)... By Shapi.pdf
Hearing loss (Ear Nose and Throat)... By Shapi.pdfShapi. MD
 
Allergic Rhinitis( Ear Nose and Throat).... By Shapi.pdf
Allergic Rhinitis( Ear Nose and Throat).... By Shapi.pdfAllergic Rhinitis( Ear Nose and Throat).... By Shapi.pdf
Allergic Rhinitis( Ear Nose and Throat).... By Shapi.pdfShapi. MD
 
Otitis Media and Otitis Externa... By Shapi.pdf
Otitis Media and Otitis Externa... By Shapi.pdfOtitis Media and Otitis Externa... By Shapi.pdf
Otitis Media and Otitis Externa... By Shapi.pdfShapi. MD
 
HERPES ZOSTER OTICUS (Ramsey Hunt's Syndrome).. By Shapi.pdf
HERPES ZOSTER OTICUS (Ramsey Hunt's Syndrome).. By Shapi.pdfHERPES ZOSTER OTICUS (Ramsey Hunt's Syndrome).. By Shapi.pdf
HERPES ZOSTER OTICUS (Ramsey Hunt's Syndrome).. By Shapi.pdfShapi. MD
 
Bronchiectasis (Respiratory Medicine).....By Shapi.pdf
Bronchiectasis (Respiratory Medicine).....By Shapi.pdfBronchiectasis (Respiratory Medicine).....By Shapi.pdf
Bronchiectasis (Respiratory Medicine).....By Shapi.pdfShapi. MD
 
Introduction to GI Medicine.... By Shapi.pdf
Introduction to GI Medicine.... By Shapi.pdfIntroduction to GI Medicine.... By Shapi.pdf
Introduction to GI Medicine.... By Shapi.pdfShapi. MD
 
Hypoglycemia (As in the ER)...... By Shapi.pdf
Hypoglycemia (As in the ER)...... By Shapi.pdfHypoglycemia (As in the ER)...... By Shapi.pdf
Hypoglycemia (As in the ER)...... By Shapi.pdfShapi. MD
 
Common Presentations (As in the ER)... By Shapi.pdf
Common Presentations (As in the ER)... By Shapi.pdfCommon Presentations (As in the ER)... By Shapi.pdf
Common Presentations (As in the ER)... By Shapi.pdfShapi. MD
 
Biochemistry of Carbohydrates.. By Shapi.pdf
Biochemistry of Carbohydrates.. By Shapi.pdfBiochemistry of Carbohydrates.. By Shapi.pdf
Biochemistry of Carbohydrates.. By Shapi.pdfShapi. MD
 
Anatomy of the GLUTEAL REGION........ By Shapi.pdf
Anatomy of the GLUTEAL REGION........ By Shapi.pdfAnatomy of the GLUTEAL REGION........ By Shapi.pdf
Anatomy of the GLUTEAL REGION........ By Shapi.pdfShapi. MD
 
BioChemistry of Lipids......... By Shapi.
BioChemistry of Lipids......... By Shapi.BioChemistry of Lipids......... By Shapi.
BioChemistry of Lipids......... By Shapi.Shapi. MD
 
Development Urinary system by Shapi. MD.pdf
Development Urinary system by Shapi. MD.pdfDevelopment Urinary system by Shapi. MD.pdf
Development Urinary system by Shapi. MD.pdfShapi. MD
 
DEVELOPMENT OF RESPIRATORY SYSTEM by Shapi. MD.pdf
DEVELOPMENT OF RESPIRATORY SYSTEM by Shapi. MD.pdfDEVELOPMENT OF RESPIRATORY SYSTEM by Shapi. MD.pdf
DEVELOPMENT OF RESPIRATORY SYSTEM by Shapi. MD.pdfShapi. MD
 
Gametogenesis 2nd.pdf
Gametogenesis 2nd.pdfGametogenesis 2nd.pdf
Gametogenesis 2nd.pdfShapi. MD
 
Bilaminar and trilaminar discs formation.pdf
Bilaminar and trilaminar discs formation.pdfBilaminar and trilaminar discs formation.pdf
Bilaminar and trilaminar discs formation.pdfShapi. MD
 
Gametogenesis and Pre-ebryonic life by Shapi. MDpdf
Gametogenesis and Pre-ebryonic life by Shapi. MDpdfGametogenesis and Pre-ebryonic life by Shapi. MDpdf
Gametogenesis and Pre-ebryonic life by Shapi. MDpdfShapi. MD
 
NOTOCHORD, NEURULATION AND NTDs by Shapi. MD.pdf
NOTOCHORD, NEURULATION AND NTDs by Shapi. MD.pdfNOTOCHORD, NEURULATION AND NTDs by Shapi. MD.pdf
NOTOCHORD, NEURULATION AND NTDs by Shapi. MD.pdfShapi. MD
 
Congenital Anomalies.pdf
Congenital Anomalies.pdfCongenital Anomalies.pdf
Congenital Anomalies.pdfShapi. MD
 
Development & histology of GIT & clinical considerations by Shapi. MD.pdf
Development & histology of GIT & clinical considerations by Shapi. MD.pdfDevelopment & histology of GIT & clinical considerations by Shapi. MD.pdf
Development & histology of GIT & clinical considerations by Shapi. MD.pdfShapi. MD
 
WRIST JOINT, CARPAL BONEs AND HAND by Shapi.pdf
WRIST JOINT, CARPAL BONEs AND HAND by Shapi.pdfWRIST JOINT, CARPAL BONEs AND HAND by Shapi.pdf
WRIST JOINT, CARPAL BONEs AND HAND by Shapi.pdfShapi. MD
 

More from Shapi. MD (20)

Hearing loss (Ear Nose and Throat)... By Shapi.pdf
Hearing loss (Ear Nose and Throat)... By Shapi.pdfHearing loss (Ear Nose and Throat)... By Shapi.pdf
Hearing loss (Ear Nose and Throat)... By Shapi.pdf
 
Allergic Rhinitis( Ear Nose and Throat).... By Shapi.pdf
Allergic Rhinitis( Ear Nose and Throat).... By Shapi.pdfAllergic Rhinitis( Ear Nose and Throat).... By Shapi.pdf
Allergic Rhinitis( Ear Nose and Throat).... By Shapi.pdf
 
Otitis Media and Otitis Externa... By Shapi.pdf
Otitis Media and Otitis Externa... By Shapi.pdfOtitis Media and Otitis Externa... By Shapi.pdf
Otitis Media and Otitis Externa... By Shapi.pdf
 
HERPES ZOSTER OTICUS (Ramsey Hunt's Syndrome).. By Shapi.pdf
HERPES ZOSTER OTICUS (Ramsey Hunt's Syndrome).. By Shapi.pdfHERPES ZOSTER OTICUS (Ramsey Hunt's Syndrome).. By Shapi.pdf
HERPES ZOSTER OTICUS (Ramsey Hunt's Syndrome).. By Shapi.pdf
 
Bronchiectasis (Respiratory Medicine).....By Shapi.pdf
Bronchiectasis (Respiratory Medicine).....By Shapi.pdfBronchiectasis (Respiratory Medicine).....By Shapi.pdf
Bronchiectasis (Respiratory Medicine).....By Shapi.pdf
 
Introduction to GI Medicine.... By Shapi.pdf
Introduction to GI Medicine.... By Shapi.pdfIntroduction to GI Medicine.... By Shapi.pdf
Introduction to GI Medicine.... By Shapi.pdf
 
Hypoglycemia (As in the ER)...... By Shapi.pdf
Hypoglycemia (As in the ER)...... By Shapi.pdfHypoglycemia (As in the ER)...... By Shapi.pdf
Hypoglycemia (As in the ER)...... By Shapi.pdf
 
Common Presentations (As in the ER)... By Shapi.pdf
Common Presentations (As in the ER)... By Shapi.pdfCommon Presentations (As in the ER)... By Shapi.pdf
Common Presentations (As in the ER)... By Shapi.pdf
 
Biochemistry of Carbohydrates.. By Shapi.pdf
Biochemistry of Carbohydrates.. By Shapi.pdfBiochemistry of Carbohydrates.. By Shapi.pdf
Biochemistry of Carbohydrates.. By Shapi.pdf
 
Anatomy of the GLUTEAL REGION........ By Shapi.pdf
Anatomy of the GLUTEAL REGION........ By Shapi.pdfAnatomy of the GLUTEAL REGION........ By Shapi.pdf
Anatomy of the GLUTEAL REGION........ By Shapi.pdf
 
BioChemistry of Lipids......... By Shapi.
BioChemistry of Lipids......... By Shapi.BioChemistry of Lipids......... By Shapi.
BioChemistry of Lipids......... By Shapi.
 
Development Urinary system by Shapi. MD.pdf
Development Urinary system by Shapi. MD.pdfDevelopment Urinary system by Shapi. MD.pdf
Development Urinary system by Shapi. MD.pdf
 
DEVELOPMENT OF RESPIRATORY SYSTEM by Shapi. MD.pdf
DEVELOPMENT OF RESPIRATORY SYSTEM by Shapi. MD.pdfDEVELOPMENT OF RESPIRATORY SYSTEM by Shapi. MD.pdf
DEVELOPMENT OF RESPIRATORY SYSTEM by Shapi. MD.pdf
 
Gametogenesis 2nd.pdf
Gametogenesis 2nd.pdfGametogenesis 2nd.pdf
Gametogenesis 2nd.pdf
 
Bilaminar and trilaminar discs formation.pdf
Bilaminar and trilaminar discs formation.pdfBilaminar and trilaminar discs formation.pdf
Bilaminar and trilaminar discs formation.pdf
 
Gametogenesis and Pre-ebryonic life by Shapi. MDpdf
Gametogenesis and Pre-ebryonic life by Shapi. MDpdfGametogenesis and Pre-ebryonic life by Shapi. MDpdf
Gametogenesis and Pre-ebryonic life by Shapi. MDpdf
 
NOTOCHORD, NEURULATION AND NTDs by Shapi. MD.pdf
NOTOCHORD, NEURULATION AND NTDs by Shapi. MD.pdfNOTOCHORD, NEURULATION AND NTDs by Shapi. MD.pdf
NOTOCHORD, NEURULATION AND NTDs by Shapi. MD.pdf
 
Congenital Anomalies.pdf
Congenital Anomalies.pdfCongenital Anomalies.pdf
Congenital Anomalies.pdf
 
Development & histology of GIT & clinical considerations by Shapi. MD.pdf
Development & histology of GIT & clinical considerations by Shapi. MD.pdfDevelopment & histology of GIT & clinical considerations by Shapi. MD.pdf
Development & histology of GIT & clinical considerations by Shapi. MD.pdf
 
WRIST JOINT, CARPAL BONEs AND HAND by Shapi.pdf
WRIST JOINT, CARPAL BONEs AND HAND by Shapi.pdfWRIST JOINT, CARPAL BONEs AND HAND by Shapi.pdf
WRIST JOINT, CARPAL BONEs AND HAND by Shapi.pdf
 

Recently uploaded

Biting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfBiting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfadityarao40181
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersSabitha Banu
 
Painted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaPainted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaVirag Sontakke
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxJiesonDelaCerna
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
internship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerinternship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerunnathinaik
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentInMediaRes1
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatYousafMalik24
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,Virag Sontakke
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxmanuelaromero2013
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfMahmoud M. Sallam
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 

Recently uploaded (20)

Biting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfBiting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdf
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginners
 
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
 
Painted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of IndiaPainted Grey Ware.pptx, PGW Culture of India
Painted Grey Ware.pptx, PGW Culture of India
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 
OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptx
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
internship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerinternship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developer
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media Component
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice great
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptx
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdf
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 

Shock (General Overview)... By Shapi.pdf

  • 1. EMERGENCY MEDICINE • SHOCK • Types of shock Dr. Chongo Shapi (BSc.HB, MBChB). Medical Doctor 21 March 2024 1 Dr. Chongo Shapi (BSc. HB, MBChB)
  • 2. INTRODUCTION • Circulatory failure resulting in inadequate organ perfusion. Often defined by Reduced BP— systolic <90mmHg—or mean arterial pressure (MAP) <65mmHg—with evidence of tissue hypoperfusion, eg mottled skin, urine output (UO) of <0.5mL/kg/h, serum lactate >2mmol/L. 21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 2
  • 3. CONT’ • Signs: Reduced GCS/agitation, pallor, cool peripheries, tachycardia, slow capillary refill, tachypnoea, oliguria. • MAP = cardiac output (CO) ≈ systemic vascular resistance (SVR). CO = stroke volume ≈ heart rate. • Therefore, shock can result from inadequate CO or a loss of SVR, or both. 21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 3
  • 4. CONT’ Inadequate cardiac output • Hypovolaemia: • Bleeding: trauma, ruptured aortic aneurysm, GI bleed. • Fluid loss: vomiting, burns, ‘third-space’ losses, eg pancreatitis, heat exhaustion. • Pump failure: • Cardiogenic shock, eg ACS, arrhythmias, aortic dissection, acute valve failure. • Secondary causes, eg PE, tension pneumothorax, cardiac tamponade. 21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 4
  • 5. CONT’ • Peripheral circulatory failure (loss of SVR) • Sepsis: Infection with any organism can cause acute vasodilation from inflammatory cytokines. Gram –ve’s can produce endotoxin, causing sudden and severe shock but without signs of infection (fever, Raised WCC). Classically patients with sepsis are warm & vasodilated, but may be cold & shut down. • Other diseases, eg pancreatitis, can give a similar picture associated with the inflammatory cascade. 21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 5
  • 6. CONT’ • Anaphylaxis: • Neurogenic: Eg spinal cord injury, epidural or spinal anaesthesia. • Endocrine failure: Addison’s disease, p836 or hypothyroidism; • Other: Drugs, eg anaesthetics, antihypertensives, cyanide poisoning. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 6
  • 7. APPROACH • With shock we are dealing primarily with ‘C ’ so get large-bore IV access ≈2 and check ECG for rate, rhythm (very fast or very slow will compromise cardiac output), and signs of ischaemia. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 7
  • 8. CONT’ • General review: Cold and clammy suggests cardiogenic shock or fluid loss. Look for signs of anaemia or dehydration, eg skin turgor, postural hypotension? Warm and well perfused, with bounding pulse points to septic shock. • Any features suggestive of anaphylaxis— history, urticaria, angioedema, wheeze? 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 8
  • 9. CONT’ • CVS: Usually tachycardic (unless on B-blocker, or in spinal shock— and hypotensive. • But in the young and fit, or pregnant women, the systolic BP may remain normal, although the pulse pressure will narrow, with up to 30% blood volume depletion. • Difference between arms (>20mmHg)—aortic dissection? • JVP or central venous pressure: If raised, cardiogenic shock likely. • Check abdomen: Any signs of trauma, or aneurysm? Any evidence of GI bleed? 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 9
  • 10. MANAGEMENT • Depends on the type of shock: a) Septic shock: b) Anaphylaxis: c) Cardiogenic shock: d) Hypovolaemic shock 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 10
  • 11. HYPOVOLEMIC SHOCK 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 11
  • 12. HYPOVOLEMIC SHOCK • Identify and treat underlying cause. Raise the legs. • Give fluid bolus 10–15mL/kg crystalloid via large peripheral line, if shock improves, • repeat, titrate to HR (aim <100), BP (aim SBP >90) and UO (aim >0.5mL/kg/h). • If no improvement after 2 boluses, consider referral to ICU 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 12
  • 13. HAEMORRHAGIC SHOCK 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 13
  • 14. HAEMORRHAGIC SHOCK • Stop bleeding if possible. Identification of grade is significant. • If still shocked despite 2L crystalloid or present with class III/IV shock then crossmatch blood (request O Rh–ve in an emergency). • Give FFP with red cells (1 : 1 ratio); aim for platelets >100 and fibrinogen >1 (guided by results, but eg 1 pool of platelets and 2 pools of cryoprecipitate per 6–8 units of red cells). • Consider tranexamic acid 2g IV. Discuss with haematology early. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 14
  • 15. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 15
  • 16. SHOCK SEPSIS 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 16
  • 17. SEPSIS • Sepsis Life-threatening organ dysfunction caused by a dysregulated host response to infection. • Sepsis is a major killer. There are >150 000 cases of sepsis in the UK each year resulting in >44 000 deaths, and much morbidity. • Septic shock Sepsis in combination with: a) EITHER lactate >2mmol/L despite adequate fluid resuscitation b) OR the patient is requiring vasopressors to maintain MAP ≥65mmHg. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 17
  • 18. CONT’ • Many sepsis-related deaths could be prevented with earlier treatment. Often, the key failure in sepsis management is not recognizing sepsis in time. • Early warning scores help identify inpatients who are becoming septic. • Have a low threshold for assessing for sepsis if: a) The patient has communication difficulties: limited English; limited verbal communication or cognitive impairment b) The patient is immunosuppressed, on chemotherapy, or an IV drug user c) The patient recently had surgery or is pregnant/recently gave birth d) The patient has indwelling lines/other foreign material. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 18
  • 19. ASSESSING RISK IN SEPSIS MODERATE TO HIGH RISK CRITERIA • Reports of altered mental state or acute deterioration in functional status • Respiratory rate (RR) 21–24 • Systolic blood pressure (SBP) 91–100mmHg • Heart rate 91–130bpm or new arrhythmia. • Urine output: nil for 12– 18h; 0.5–1.0mL/kg/h if catheterized HIGH RISK CRITERIA • Objective evidence of altered mental state • RR>24; new requirement for FiO2 >40% to keep sats >92% (>88% in COPD) • SBP <90 or >40mmHg less than baseline • Heart rate >130bpm • Urine output: nil for 18h; <0.5mL/kg/h if catheterized 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 19
  • 20. CONT’ • Local signs of infection, incl. redness, swelling, or discharge around wound • Rigors, or temperature <36°C • Impaired immunity (illness or drugs) • Recent surgery/trauma/invasive procedure • Mottled, ashen, or cyanotic skin. Non- blanching rash 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 20
  • 21. CONT’ • High risk: At least one high-risk criterion OR at least two moderate- to high-risk criteria with AKI or LACTATE >2. • Moderate to high risk: At least one moderate- to high-risk criterion. • Low risk: No moderate- or high-risk criteria. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 21
  • 22. ACUTE MANAGEMENT IN SEPSIS • Early recognition and treatment is key. • Antibiotics: These should be broad spectrum and start within 1h. Consider covering for non-bacterial microbes, eg give aciclovir if HSV encephalitis is suspected. • Fluids: Give within 1h if high risk with SBP <90, AKI, or lactate >2 (consider if <2). ❑Give 500mL boluses of crystalloids with 130– 154mmol/L sodium (eg 0.9% saline) over 15mins. Caution in heart failure. ❑ If no improvement after two boluses, speak with a senior. (Possible use of inotropes) 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 22
  • 23. CONT’ • Oxygen: Give oxygen as required for target saturations. These will be 94–98% (or 88–92% if the patient is at risk of CO2 retention, eg in severe COPD). • Critical care review: Speak with critical care early if intensive care support (eg inotropes, ventilation, haemofiltration, intensive monitoring) may be required. • Surgical involvement: Eg emergency wound debridement. • Manage acute complications: Shock, AKI, DIC, ARDS, arrhythmias etc (may spontaneously resolve when sepsis improves). 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 23
  • 24. SHOCK ANAPHYLACTIC SHOCK 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 24
  • 25. ANAPHYLACTIC SHOCK • Type I IgE-mediated hypersensitivity reaction. Release of histamine and other agents causes: capillary leak; wheeze; cyanosis; oedema (larynx, lids, tongue, lips); urticaria. • More common in atopic individuals. An anaphylactoid reaction results from direct release of mediators from inflammatory cells, without involving antibodies, usually in response to a drug, eg acetylcysteine. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 25
  • 26. CONT’ • Examples of precipitants: a) Drugs, eg penicillin, and contrast media in radiology. b) Latex. c) Stings, eggs, fish, peanuts, strawberries, semen (rare). 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 26
  • 27. CONT’ • Signs and symptoms a) Itching, sweating, diarrhoea and vomiting, erythema, urticaria, oedema. b) Wheeze, laryngeal obstruction, cyanosis. Tachycardia, hypotension. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 27
  • 28. MANAGEMENT • Secure the airway—give 100% O2 but Intubate if respiratory obstruction imminent. • Remove the cause; raising the feet may help restore the circulation. • Give adrenaline IM 0.5mg (ie 0.5mL of 1:1000). Repeat every 5min, if needed as guided by BP, pulse, and respiratory function, until better • Give Chlorphenamine 10mg IV and hydrocortisone 200mg IV 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 28
  • 29. CONT’ • IVI (0.9% saline, eg 500mL over ¼h; up to 2L may be needed) Titrate against blood pressure. • If wheeze, treat for asthma. May require ventilatory support. • If still hypotensive, admission to ICU and an IVI of adrenaline may be needed ± aminophylline and nebulized salbutamol 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 29
  • 30. CONT’ • When stable, admit to ward. Monitor ECG • Measure serum tryptase 1–6h after suspected anaphylaxis • Continue chlorphenamine 4mg/6h PO if itching • Suggest a ‘MedicAlert’ bracelet naming the culprit allergen • Teach about self-injected adrenaline (eg 0.3mg, Epipen®) to prevent a fatal attack • Skin-prick tests showing specific IgE help identify allergens to avoid 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 30
  • 31. CONT’ • Adrenaline (=epinephrine) is given IM and NOT IV unless the patient is severely ill, or has no pulse. The IV dose is different: 100mcg/min—titrating with the response. • This is 0.5mL of 1 : 10 000 solution IV per minute. Stop as soon as a response has been obtained. • If on a B-blocker, consider salbutamol IV in place of adrenaline. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 31
  • 32. THE END! • Reference as per Oxford Clinical Medicine. 22 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 32
  • 33. Thanks 21 March 2024 Dr. Chongo Shapi (BSc. HB, MBChB) 33